IBDEI13Y ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19547,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19547,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,19547,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,19547,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,19548,0)
 ;;=204.02^^105^1232^2
 ;;^UTILITY(U,$J,358.3,19548,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19548,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,19548,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,19548,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,19549,0)
 ;;=204.12^^105^1232^17
 ;;^UTILITY(U,$J,358.3,19549,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19549,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,19549,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,19549,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,19550,0)
 ;;=204.20^^105^1232^114
 ;;^UTILITY(U,$J,358.3,19550,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19550,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,19550,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,19550,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,19551,0)
 ;;=204.21^^105^1232^116
 ;;^UTILITY(U,$J,358.3,19551,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19551,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,19551,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,19551,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,19552,0)
 ;;=204.22^^105^1232^115
 ;;^UTILITY(U,$J,358.3,19552,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19552,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,19552,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,19552,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,19553,0)
 ;;=205.02^^105^1232^5
 ;;^UTILITY(U,$J,358.3,19553,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19553,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,19553,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,19553,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,19554,0)
 ;;=205.12^^105^1232^20
 ;;^UTILITY(U,$J,358.3,19554,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19554,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,19554,1,5,0)
 ;;=5^CML,In Relapse
 ;;^UTILITY(U,$J,358.3,19554,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,19555,0)
 ;;=284.81^^105^1232^14
 ;;^UTILITY(U,$J,358.3,19555,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19555,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,19555,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,19555,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,19556,0)
 ;;=284.89^^105^1232^13
 ;;^UTILITY(U,$J,358.3,19556,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19556,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,19556,1,5,0)
 ;;=5^Aplastic Anemia d/t Chronic Disease
 ;;^UTILITY(U,$J,358.3,19556,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,19557,0)
 ;;=289.84^^105^1232^119
 ;;^UTILITY(U,$J,358.3,19557,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19557,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,19557,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,19557,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,19558,0)
 ;;=V10.91^^105^1232^67
 ;;^UTILITY(U,$J,358.3,19558,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19558,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,19558,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,19558,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,19559,0)
 ;;=V10.91^^105^1232^66
 ;;^UTILITY(U,$J,358.3,19559,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19559,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,19559,1,5,0)
 ;;=5^H/O Malignant Neoplasm,Unspec
 ;;^UTILITY(U,$J,358.3,19559,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,19560,0)
 ;;=465.9^^105^1233^70
 ;;^UTILITY(U,$J,358.3,19560,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19560,1,4,0)
 ;;=4^465.9
 ;;
 ;;$END ROU IBDEI13Y
